Japan approves Bristol-Myers' nivolumab, hep C combo; CMS tweaks Sunshine Act;

> Bristol-Myers Squibb's ($BMS) Opdivo (nivolumab), an immuno-oncology drug for advanced melanoma, has scored its first regulatory green light, grabbing Japanese approval. Release

> Japan has approved Bristol-Myers Squibb's ($BMS) next-gen hepatitis C cocktail, made up of Daklinza and Sunvepra. Release

> The Centers for Medicare & Medicaid Services (CMS) announced plans to enact changes to the Open Payments program, including the Sunshine exemption for continuing medical education. More

> AstraZeneca ($AZN) will hold a Twitter chat to answer questions about its home-delivery program. Blog

> Celgene's ($CELG) Imnovid, a multiple myeloma drug, was rejected by the Scottish Medicines Consortium despite the recognition of its ability to significantly improve chances of survival. Sanofi's ($SNY) Lemtrada and Roche's ($RHHBY) MabThera both received positive recommendations. Story

> Takeda Pharmaceutical is taking heat for publishing a 74-page report on a probe of a "misleading" ad for its Blopress high blood pressure medicine--exclusively in Japanese. More (sub. req.)

And Finally... Taiwan's Gala Television has been fined $200,000 for using the name of a Taiwanese pharmaceutical company as a title sponsor for a singing contest. News

Suggested Articles

Rather than accept a filing based on phase 1/2 data, the FDA wants Novartis to run a phase 3 for a market-expanding version of gene therapy Zolgensma.

After sifting through the data, one analyst figures the latest Opdivo-Keytruda showdown in kidney cancer might come down to commercial execution.

Call it a fall sports bounce. TV ad spending bumped up in August with the partial return of professional sports, and that included pharma buyers.